Abstract |
Forty two ovarian cancer patients with residual disease after the first laparotomy were treated with the combination of cisplatin (80 mg/m2 day 1), adriamycin (50 mg/m2 i.v. day 2) and cyclophosphamide (500 mg/m2 i.v. day 2) (PAC). Forty women were considered evaluable for analysis, with an overall response rate (partial, plus complete responses) of 62.5%. Twelve patients (30%) obtained a complete response (histologically confirmed after second look surgery in 6 cases, surgical complete response, residual tumor completely resected in the second look-in 5 cases and maintained complete clinical remission without second look confirmation in 1 case). Main side effects were nausea and vomiting (90%), leukopenia (70%), mucositis (45%), and anemia (37%). Seventeen percent of the patients were free of disease at 60 months, after a median follow-up of 48 months. The prognostic factors that showed significant influence on survival were the Karnofski index (90-100 vs 80 or less), stage of the disease (II + III vs IV) and the volume of residual tumor after the first surgical procedure (less than or equal to 2 cms vs greater than 2 cms). Patients who achieved a complete remission have not reached the median 5 years survival, which was 10 months for the remaining patients. These results confirm the activity of PAC in ovarian cancer, mainly in those patients with residual tumor of less than 2 cms and good performance status.
|
Authors | E Diaz-Rubio, M Escudero, M Martin-Jimenez, J A Vidart, J L Gonzalez-Larriba, M A Herraiz, J M Lopez Vega, F Bullon |
Journal | European journal of gynaecological oncology
(Eur J Gynaecol Oncol)
Vol. 10
Issue 6
Pg. 424-32
( 1989)
ISSN: 0392-2936 [Print] Singapore |
PMID | 2627975
(Publication Type: Journal Article)
|
Chemical References |
- Doxorubicin
- Cyclophosphamide
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cisplatin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Middle Aged
- Ovarian Neoplasms
(drug therapy, mortality)
|